1-855-378-42281-855-378-4228
One of the outpatient treatment alternatives for individuals in New Bloomfield struggling with opioid abuse and addiction is called opioid maintenance therapy. Licensed facilities and doctors are certified to dispense certain medications to opioid dependent individuals, many of which are opioid-based also and are addictive. With low amounts the individual does not feel high and also does not have intense cravings and is not experiencing opioid withdrawal. Methadone is the first med administered for this purpose, but there are other options currently to pick from.
Methadone is an opioid and is meant to be taken at an out-patient medical center certified to administer the drug, which is taken on a daily basis in liquid or pill form. The cost of the med is approximately $150 monthly. Buprenorphine is also an opioid based drug, and is in pill form often taken one day on, one day off. But different from Methadone which can only be administered in well-regulated medical centers, Buprenorphine can be and is prescribed and administered in doctor's offices. The cost monthly of buprenorphine is about $300 monthly for the generic version of the med. There is also a version of buprenorphine that contains naloxone, that is a drug which blocks the effects of opioids. Someone taking this version of the drug, AKA Suboxone, would find it more difficult to feel high from opioids if they relapsed while taking the drug. It is also taken on a daily basis, and is priced approximately $450 a month. Naltrexone is an additional med taken in opioid maintenance therapy, but unlike the other drugs mentioned here it is an opioid blocker and isn't an opiate. There is an option to take this drug as a monthly injection, which is called Vivitrol. As an opioid blocker, the drug prevents a person from experience being high from opioids, and in turn lowers the risk associated with relapse. This daily injection costs anywhere from $1000 to $1200 /month.
For All Alcohol and Drug Rehab Centers In New Bloomfield, Click Here.
